Zacks Investment Research on MSN
MMED's latest study supports the strength of 780G SmartGuard algorithm
MiniMed Group, Inc. MMED recently announced results from a new randomized crossover study showing that glycemic outcomes ...
Twenty-four adult participants with type 1 diabetes were randomized to use either the Simplera Sync™ or Instinct sensor for a six-week period, then crossed over to the alternate sensor for an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results